← All sarcoma trials
Recruiting nowN/AAges 10 Years and up

Implantable Microdevice for the Delivery of Drugs and Their Effect on Tumors in Patients With Metastatic or Recurrent Sarcoma

Sponsor: M.D. Anderson Cancer Center · NCT04199026 on ClinicalTrials.gov ↗

Bring this to your care team →

Conditions studied

Metastatic SarcomaRecurrent SarcomaResectable Sarcoma

What it tests

  • Doxorubicindrug
  • Doxorubicin Hydrochloridedrug
  • Drug Delivery Microdevicedevice
  • Everolimusdrug
  • Ganitumabbiological
  • Ifosfamidedrug
  • Irinotecandrug
  • Pazopanibdrug
  • Polyethylene Glycoldrug
  • Temozolomidedrug
  • Temsirolimusdrug
  • Therapeutic Conventional Surgeryprocedure
  • Vincristinedrug

Where it's running1 site

  • M D Anderson Cancer Center

    Houston, Texas 77030

    Recruiting now
See the official eligibility language

Shown exactly as written on ClinicalTrials.gov. Your oncologist is the right person to judge whether it fits your situation.

Inclusion:

* Patients with a biopsy-confirmed recurrent or metastatic sarcoma for which surgery is indicated as a standard of care.
* 10 years of age or older
* Documented, signed, dated informed consent to participate in the microdevice study
* Eastern Cooperative Oncology Group (ECOG) performance status of =\< 2

Exclusion:

* Subjects who do not wish to undergo surgical resection, or those who are high-risk or not candidates for surgical resection
* Age \< 10 years old
* Women of childbearing potential without a negative pregnancy test; or women who are lactating
* Allergies or prior adverse drug reactions to any of the drugs loaded within the microdevice.

Updated 2026-02-19 on ClinicalTrials.gov. Always confirm current details with the study team or your oncologist.